Last reviewed · How we verify
carboxymethylcellulose 0.5% +glycerin 0.9%
carboxymethylcellulose 0.5% +glycerin 0.9% is a Artificial tear / ocular lubricant Small molecule drug developed by Allergan. It is currently FDA-approved for Dry eye syndrome / keratoconjunctivitis sicca. Also known as: Optive™ Sensitive.
Carboxymethylcellulose and glycerin work together to lubricate and hydrate the ocular surface, providing relief from dry eye symptoms.
Carboxymethylcellulose and glycerin work together to lubricate and hydrate the ocular surface, providing relief from dry eye symptoms. Used for Dry eye syndrome / keratoconjunctivitis sicca.
At a glance
| Generic name | carboxymethylcellulose 0.5% +glycerin 0.9% |
|---|---|
| Also known as | Optive™ Sensitive |
| Sponsor | Allergan |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Carboxymethylcellulose is a cellulose derivative that acts as a lubricant and demulcent, coating the cornea and conjunctiva to reduce friction and protect the ocular surface. Glycerin is a humectant that draws moisture to the eye and helps retain hydration on the tear film. Together, these agents mimic natural tears and provide sustained lubrication for symptomatic dry eye relief.
Approved indications
- Dry eye syndrome / keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Blurred vision
- Eye discomfort
Key clinical trials
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® (PHASE1)
- A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (PHASE4)
- Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms (PHASE4)
- Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboxymethylcellulose 0.5% +glycerin 0.9% CI brief — competitive landscape report
- carboxymethylcellulose 0.5% +glycerin 0.9% updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about carboxymethylcellulose 0.5% +glycerin 0.9%
What is carboxymethylcellulose 0.5% +glycerin 0.9%?
How does carboxymethylcellulose 0.5% +glycerin 0.9% work?
What is carboxymethylcellulose 0.5% +glycerin 0.9% used for?
Who makes carboxymethylcellulose 0.5% +glycerin 0.9%?
Is carboxymethylcellulose 0.5% +glycerin 0.9% also known as anything else?
What drug class is carboxymethylcellulose 0.5% +glycerin 0.9% in?
What development phase is carboxymethylcellulose 0.5% +glycerin 0.9% in?
What are the side effects of carboxymethylcellulose 0.5% +glycerin 0.9%?
Related
- Drug class: All Artificial tear / ocular lubricant drugs
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye syndrome / keratoconjunctivitis sicca
- Also known as: Optive™ Sensitive
- Compare: carboxymethylcellulose 0.5% +glycerin 0.9% vs similar drugs
- Pricing: carboxymethylcellulose 0.5% +glycerin 0.9% cost, discount & access